Evidence‐based rationale for low dose nivolumab in critically ill patients with sepsis‐induced immunosuppression

A substantial part of critically ill patients suffer from sepsis‐induced immunosuppression. Reversal of immunosuppression through PD‐1 checkpoint inhibition has been proposed as a treatment strategy to overcome immunosuppression in these patients. The PD‐1 inhibitor nivolumab, currently used in trea...

Descripción completa

Detalles Bibliográficos
Autores principales: van den Haak, Demy A. C., Otten, Leila‐Sophie, Koenen, Hans J. P. M., Smeets, Ruben L., Piet, Berber, Pickkers, Peter, Kox, Matthijs, ter Heine, Rob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264964/
https://www.ncbi.nlm.nih.gov/pubmed/37002646
http://dx.doi.org/10.1111/cts.13503

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264964/
https://www.ncbi.nlm.nih.gov/pubmed/37002646
http://dx.doi.org/10.1111/cts.13503

Ejemplares similares